CRISPR Therapeutics
CRSP
26 hedge funds and large institutions have $198M invested in CRISPR Therapeutics in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
24.7% more ownership
Funds ownership: 0% → 24.7% (+25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$60.2M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$48.6M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$15.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$13.6M |
Top Sellers
CRSP Hedge Fund Activity: Q4 2016 in Review
26 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2016, worth a combined $198M.
Buyers outnumbered sellers: 26 funds opened new CRSP positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $60.2M.
- 26 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $198M of CRISPR Therapeutics stock for Q4 2016.
- 26 funds opened new CRISPR Therapeutics positions in Q4 2016 and 0 closed out, a net change of +26 holders.
- The largest CRISPR Therapeutics buyer in Q4 2016 was NEA Management Company, an estimated $60.2M added.
Based on aggregated 13F filings for Q4 2016.